Kamran Riaz, MD
Cornea and External Diseases Specialist · Oklahoma City, OKNPI 1326276965
Payments from drug & device makers
Across 234 payments — averaging $1016.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$148K
- Novartis$32K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$32K
- Glaukos Corporation$8K
- AbbVie$7K
- Carl Zeiss Meditec, Inc.$3K
- plus $7K from 16 others
What the payments were for
- Consulting fees$53,65927%
- Speaking & faculty fees$122,37562%
- Travel & lodging$13,8407%
- Food & beverage$6,6943%
- Education$1,5001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 130 | $147,925 |
| Novartis | 4 | $32,073 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $32,072 |
| Glaukos Corporation | 9 | $7,765 |
| AbbVie(2 entities) | 5 | $7,484 |
| Carl Zeiss Meditec, Inc. | 2 | $3,236 |
| Beaver-visitec International, Inc. | 2 | $2,581 |
| The Cameron-ehlen Group, Inc. | 2 | $1,802 |
| Immunogen, Inc. | 2 | $1,037 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $619 |
| Mallinckrodt Hospital Products Inc. | 14 | $307 |
| Alcon | 7 | $263 |
| Microsurgical Technology, Inc. | 1 | $161 |
| Ocular Therapeutix, Inc. | 9 | $153 |
| NEW World Medical,inc. | 1 | $141 |
| Merz Pharmaceuticals, LLC | 1 | $81 |
| Dompe US, Inc. | 3 | $64 |
| Harrow Eye, LLC | 1 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $33 |
| Carl Zeiss Meditec USA, Inc. | 1 | $24 |
| Katena Products, Inc. (dba Corza Medical) | 2 | $21 |
| Rxsight Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$86,645
- XIIDRA$50,958
- enVista Aspire IOL$25,065
- LOTEMAX SM$18,307
- PROLENSA$12,932
- TENEO$12,065
- STELLARIS ELITE$12,065
- enVista MX60 IOL$10,307
- Tecnis IOL$5,405
- VisuMax$3,200
- FORUM$3,200
- HEALON PRO$1,802
- Tecnis Simplicity$1,802
- BLINK NUTRITEARS$850
- ENVISTA ENVY$850
- Whitestar Phacoemulsficiation System$500
- STELLARIS$244
- Kahook Dual Blade$141
- Clearpath$141
- Ahmed Glaucoma Valve$141
How this compares
Too few cornea and external diseases specialist providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 36 | $31,059 |
| Prednisolone Acetate | 534 | $22,513 |
| RestasisCyclosporine | 23 | $14,473 |
| ValacyclovirValacyclovir Hcl | 211 | $11,654 |
| EysuvisLoteprednol Etabonate | 14 | $9,817 |
| ZirganGanciclovir | 11 | $9,588 |
| Ketorolac Tromethamine | 221 | $6,827 |
| MoxifloxacinMoxifloxacin Hcl | 265 | $6,320 |
| Fluorometholone | 85 | $5,869 |
| Bromfenac Sodium | 25 | $5,247 |
| Lotemax SmLoteprednol Etabonate | 18 | $5,080 |
| Loteprednol Etabonate | 26 | $3,478 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $2,811 |
| Doxycycline Monohydrate | 97 | $2,018 |
| Brimonidine Tartrate | 80 | $1,878 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Zirgan | $147,925 | $40,64747 claims |
| AbbVieRestasis, Combigan | $7,484 | $17,28436 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $33 | $9,81714 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $32,072 | $8,55744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other cornea and external diseases specialist in Oklahoma City
- David JacksonOklahoma City$5K
- Scott VadalaOklahoma City$2K
- Ahmad Abdel-AtyOklahoma City$1K
- Rhea SiatkowskiOklahoma City$534
- Daniel CorbettTulsa$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.